Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma

Proteomics

Volumn 15, Issue 2-3, 2015, Pages 374-382

  Syed, Nazia ^a,b   Barbhuiya, Mustafa A ^a,c,d   Pinto, Sneha M ^a,e   Nirujogi, Raja Sekhar ^a,b   Renuse, Santosh ^a,f   Datta, Keshava K ^a,g   Khan, Aafaque Ahmad ^a,g   Srikumar, Kotteazeth ^b   Prasad, T S Keshava ^a,e   Kumar, M Vijaya ^h   Kumar, Rekha Vijay ^h   Chatterjee, Aditi ^a   Pandey, Akhilesh ^c   Gowda, Harsha ^a  

^a INSTITUTE OF BIOINFORMATICS   (India)

^b PONDICHERRY UNIVERSITY   (India)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

^e MANIPAL UNIVERSITY   (India)

^f AMRITA UNIVERSITY   (India)

^g KIIT UNIVERSITY   (India)

^h KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Biomedicine; In vivo labeling; Mass spectrometry; Post translational modifications

Indexed keywords

EPHRIN RECEPTOR A2; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; EPHRIN A2;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE OVEREXPRESSION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; CELL LINE; ESOPHAGUS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; EPHRIN-A2; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MASS SPECTROMETRY; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84921283090     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400379     Document Type: Article

References (53)

1. Pennathur, A., Gibson, M. K., Jobe, B. A., Luketich, J. D., Oesophageal carcinoma. Lancet 2013, 381, 400-412.
2. Jemal, A., Bray, F., Center, M. M., Ferlay, J. et al., Global cancer statistics.CA Cancer J. Clin. 2011, 61, 69-90.
3. Kashyap, M. K., Marimuthu, A., Kishore, C. J., Peri, S. et al., Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol. Ther. 2009, 8, 36-46.
4. Pawar, H., Kashyap, M. K., Sahasrabuddhe, N. A., Renuse, S. et al., Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol. Ther. 2011, 12, 510-522.
5. Kashyap, M. K., Pawar, H. A., Keerthikumar, S., Sharma, J. et al., Evaluation of protein expression pattern of stanniocalcin 2, insulin-like growth factor-binding protein 7, inhibin beta A and four and a half LIM domains 1 in esophageal squamous cell carcinoma. Cancer Biomark. 2012, 12, 1-9.
6. Kashyap, M. K., Harsha, H. C., Renuse, S., Pawar, H. et al., SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol. Ther. 2010, 10, 796-810.
7. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J. et al., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Engl. J. Med. 2001, 344, 1038-1042.
8. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A. et al., Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl. J. Med. 2010, 363, 809-819.
9. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H. et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl. J. Med. 2001, 344, 783-792.
10. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P. et al., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl. J. Med. 2003, 349, 427-434.
11. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S. et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 2004, 350, 2129-2139.
12. Song, Y., Li, L., Ou, Y., Gao, Z. et al., Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014, 509, 91-95.
13. Lin, D. C., Hao, J. J., Nagata, Y., Xu, L. et al., Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 2014, 46, 467-473.
14. Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S. et al., Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 2013, 45, 478-486.
15. Agrawal, N., Jiao, Y., Bettegowda, C., Hutfless, S. M. et al., Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012, 2, 899-905.
16. Walters, D. K., Goss, V. L., Stoffregen, E. P., Gu, T. L. et al., Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk. Res. 2006, 30, 1097-1104.
17. Harsha, H. C., Pandey, A., Phosphoproteomics in cancer. Mol. Oncol. 2010, 4, 482-495.
18. Chaerkady, R., Harsha, H. C., Nalli, A., Gucek, M. et al., A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J. Proteome Res. 2008, 7, 4289-4298.
19. Geiger, T., Cox, J., Ostasiewicz, P., Wisniewski, J. R., Mann, M., Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods 2010, 7, 383-385.
20. Harsha, H. C., Pinto, S. M., Pandey, A., Proteomic strategies to characterize signaling pathways. Methods Mol. Biol. 2013, 1007, 359-377.
21. Iida, M., Brand, T. M., Campbell, D. A., Li, C., Wheeler, D. L., Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 2013, 32, 759-767.
22. Sancier, F., Dumont, A., Sirvent, A., Paquay de Plater, L., et al., Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells. PLoS One 2011, 6, e17237.
23. Kim, J. M., Kang, D. W., Long, L. Z., Huang, S. M. et al., Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma. Hum. Pathol. 2011, 42, 315-323.
24. Kullander, K., Klein, R., Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 2002, 3, 475-486.
25. Lindberg, R. A., Hunter, T., cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol. Cell. Biol. 1990, 10, 6316-6324.
26. Pandey, A., Shao, H., Marks, R. M., Polverini, P. J., Dixit, V. M., Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 1995, 268, 567-569.
27. Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R. et al., The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19, 6043-6052.
28. Brantley-Sieders, D. M., Caughron, J., Hicks, D., Pozzi, A., et al., EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J. Cell Sci. 2004, 117, 2037-2049.
29. Pandey, A., Lazar, D. F., Saltiel, A. R., Dixit, V. M., Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J. Biol. Chem. 1994, 269, 30154-30157.
30. Pandey, A., Duan, H., Dixit, V. M., Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase. J. Biol. Chem. 1995, 270, 19201-19204.
31. Hunter, S. G., Zhuang, G., Brantley-Sieders, D., Swat, W., et al., Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol. Cell. Biol. 2006, 26, 4830-4842.
32. Cheng, C., Ansari, M. M., Cooper, J. A., Gong, X., EphA2 and Src regulate equatorial cell morphogenesis during lens development. Development 2013, 140, 4237-4245.
33. Du, X., Baldwin, C., Hooker, E., Glorion, P., Lemay, S., Basal and Src kinase-mediated activation of the EphA2 promoter requires a cAMP-responsive element but is CREB-independent. J. Cell. Biochem. 2011, 112, 1268-1276.
34. Pratt, R. L., Kinch, M. S., Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002, 21, 7690-7699.
35. Cheng, Q., Sasaki, Y., Shoji, M., Sugiyama, Y. et al., Cdk5/p35 and Rho-kinase mediate ephrin-A5-induced signaling in retinal ganglion cells. Mol. Cell. Neurosci. 2003, 24, 632-645.
36. Carter, N., Nakamoto, T., Hirai, H., Hunter, T., EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat. Cell Biol. 2002, 4, 565-573.
37. Miyazaki, T., Kato, H., Fukuchi, M., Nakajima, M., Kuwano, H., EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer 2003, 103, 657-663.
38. Miyazaki, T., Kato, H., Kimura, H., Inose, T. et al., Evaluation of tumor malignancy in esophageal squamous cell carcinoma using different characteristic factors. Anticancer Res. 2005, 25, 4005-4011.
39. Xu, F., Zhong, W., Li, J., Shanshen, Z. et al., Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res. 2005, 25, 2943-2950.
40. Amato, K. R., Wang, S., Hastings, A. K., Youngblood, V. M. et al., Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J. Clin. Invest. 2014, 124, 2037-2049.
41. Wykosky, J., Gibo, D. M., Stanton, C., Debinski, W., EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 2005, 3, 541-551.
42. Abraham, S., Knapp, D. W., Cheng, L., Snyder, P. W. et al., Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin. Cancer Res. 2006, 12, 353-360.
43. Kinch, M. S., Moore, M. B., Harpole, D. H., Jr., Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 2003, 9, 613-618.
44. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003, 63, 4481-4489.
45. Kataoka, H., Igarashi, H., Kanamori, M., Ihara, M. et al., Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004, 95, 136-141.
46. Thaker, P. H., Deavers, M., Celestino, J., Thornton, A. et al., EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 2004, 10, 5145-5150.
47. Han, L., Dong, Z., Qiao, Y., Kristensen, G. B. et al., The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol. Oncol. 2005, 99, 278-286.
48. Landen, C. N., Kinch, M. S., Sood, A. K., EphA2 as a target for ovarian cancer therapy. Expert Opin. Ther. Targets 2005, 9, 1179-1187.
49. Zeng, G., Hu, Z., Kinch, M. S., Pan, C. X. et al., High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am. J. Pathol. 2003, 163, 2271-2276.
50. Coffman, K. T., Hu, M., Carles-Kinch, K., Tice, D. et al., Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 2003, 63, 7907-7912.
51. Brannan, J. M., Dong, W., Prudkin, L., Behrens, C. et al., Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin. Cancer Res. 2009, 15, 4423-4430.
52. Cheng, N., Brantley, D. M., Liu, H., Lin, Q. et al., Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 2002, 1, 2-11.
53. Dobrzanski, P., Hunter, K., Jones-Bolin, S., Chang, H. et al., Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 2004, 64, 910-919.